Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549600 | 1.00 | CRBN (0.50) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30633804 | 1.00 | CRBN (0.50) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2635465 | 0.98 | CRBN (0.48) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2635466 | 0.98 | CRBN (0.48) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21238838 | 0.94 | CRBN (0.48) | CRBNOTUD7B | |
| SCHEMBL1207857 | 0.94 | CRBN (0.47) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12500998 | 0.92 | CRBN (0.55) | CRBNOTUD7BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2635797 | 0.92 | CRBN (0.46) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2635798 | 0.92 | CRBN (0.46) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21225403 | 0.90 | CRBN (0.44) | CRBNOTUD7BALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493895-B1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
| EP-2493895-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051452-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010072823-A1 | PYRAZOLE[1,5a]PYRIDINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CRBN 538/4885OTUD7B 1844/4885ALDH1A1 3830/4885 |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CRBN 538/4885OTUD7B 1844/4885ALDH1A1 3830/4885 |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CRBN 538/4885OTUD7B 1844/4885ALDH1A1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.